Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 17/20 | 1.00 |
| ▸ | MMP13 | P45452 | 16/20 | 0.54 |
| ▸ | MMP9 | P14780 | 6/20 | 0.47 |
| ▸ | MMP2 | P08253 | 5/20 | 0.47 |
| ▸ | MMP8 | P22894 | 4/20 | 0.47 |
| ▸ | MMP3 | P08254 | 3/20 | 0.47 |
| ▸ | MMP14 | P50281 | 2/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | MMP16 | P51512 | 1/20 | 0.41 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25130 | 0.98 | MMP1 (0.96) | MMP1MMP13MMP9MMP2MMP8 | |
| SCHEMBL6813051 | 0.97 | MMP1 (0.94) | MMP1MMP13MMP9MMP2MMP8 | |
| SCHEMBL6699509 | 0.92 | MMP1 (0.84) | MMP1MMP13MMP9MMP2MMP8 | |
| SCHEMBL26434 | 0.91 | MMP1 (0.83) | MMP1MMP13MMP9MMP2MMP8 | |
| SCHEMBL13556928 | 0.90 | MMP1 (0.81) | MMP1MMP13MMP9MMP2MMP8 | |
| SCHEMBL6695057 | 0.90 | MMP1 (0.81) | MMP1MMP13MMP9MMP2MMP8 | |
| SCHEMBL6876444 | 0.89 | MMP1 (0.81) | MMP1MMP13MMP9MMP2MMP8 | |
| SCHEMBL6691684 | 0.88 | MMP1 (0.79) | MMP1MMP13MMP9MMP2MMP8 | |
| SCHEMBL4783958 | 0.88 | MMP1 (0.79) | MMP1MMP13MMP9MMP2MMP8 | |
| SCHEMBL17844392 | 0.88 | MMP1 (0.77) | MMP1MMP13MMP9MMP2MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 733 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0952148-B1 | Cyclobutyl-aryloxyarylsulfonylamino hydroxamic acid derivatives | PFIZER PROD INC (US) | 2004-05-12 | — | — | EP | claimed |
| US-6156798-A | Cyclobutyl-aryloxyarylsulfonylamino hydroxamic acid derivatives | PFIZER INC (US) | 2000-12-05 | — | — | US | claimed |
| EP-0952148-A1 | Cyclobutyl-aryloxyarylsulfonylamino hydroxamic acid derivatives | Pfizer Products Inc. (US) | 1999-10-27 | — | — | EP | claimed |
| EP-0930067-A2 | MMP INHIBITORS FOR THE TREATMENT OF OCULAR ANGIOGENESIS | Pfizer Products Inc. (US) | 1999-07-21 | — | — | EP | claimed |
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250214963-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250129085-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-04-24 | — | — | US | disclosed |
| US-12037404-B2 | Human monoclonal antibodies against EphA4 and their use | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2024-07-16 | — | — | US | disclosed |
| EP-2534153-B2 | SALTS AND POLYMORPHS OF 8-FLUORO-2-{4-[(METHYLAMINO}METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-CD]INDOL-6-ONE | PFIZER (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20240109862-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2024-04-04 | — | — | US | disclosed |
| US-20240083855-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-03-14 | — | — | US | disclosed |
| EP-3590932-B1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY INC (US) | 2023-05-03 | — | — | EP | disclosed |
| US-6258824-B1 | TREATMENT OF HYPERPROLIFERATIVE DISEASES, SUCH AS CANCERS, IN MAMMALS. THIS INVENTION ALSO RELATES TO A PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS. | PFIZER INC. | 2001-07-10 | — | — | US | disclosed |
| EP-1106612-A1 | Quinoline derivatives useful for inhibiting farnesyl protein transferase | Pfizer Products Inc. (US) | 2001-06-13 | — | — | EP | disclosed |
| WO-2001040217-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | PFIZER PRODUCTS INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001034574-A1 | STABLE POLYMORPH OF N-(3-ETHYNYLPHENYLAMINO)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMINE HYDROCHLORIDE, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF | OSI PHARMACEUTICALS, INC. (US) | 2001-05-17 | — | — | WO | disclosed |
| US-6156798-A | Cyclobutyl-aryloxyarylsulfonylamino hydroxamic acid derivatives | PFIZER INC (US) | 2000-12-05 | — | — | US | disclosed |
| WO-2000047574-A1 | HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-08-17 | — | — | WO | disclosed |
| EP-0952148-A1 | Cyclobutyl-aryloxyarylsulfonylamino hydroxamic acid derivatives | Pfizer Products Inc. (US) | 1999-10-27 | — | — | EP | disclosed |
| EP-0930067-A2 | MMP INHIBITORS FOR THE TREATMENT OF OCULAR ANGIOGENESIS | Pfizer Products Inc. (US) | 1999-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214963-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | MMP1 3955/4885MMP13 4604/4885MMP9 4635/4885 |
| US-20240083855-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | ALK, JAK2, JAK1 | MMP1 2298/4885MMP13 2440/4885MMP9 2597/4885 |
| US-20250129085-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | MMP1 2061/4885MMP13 4280/4885MMP9 3879/4885 |
| US-20240109862-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | MMP1 3955/4885MMP13 4604/4885MMP9 4635/4885 |
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | MMP1 2061/4885MMP13 4280/4885MMP9 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.